Mereo BioPharma (MREO) Receivables - Net (2022 - 2023)
Mereo BioPharma's (MREO) quarterly Receivables - Net came in at $9.9 million in Q2 2023, up 1005.09% quarter-over-quarter from $893771.4 in Q4 2022.
Powered by 
Analysis
Mereo BioPharma (MREO) Receivables - Net (2022 - 2023) Analysis & Trends
Mereo BioPharma (MREO) has reported Receivables - Net for 2 consecutive years, with $9.9 million the latest figure, recorded in Q2 2023.
- On a quarterly basis, Receivables - Net changed N/A year-over-year to $9.9 million in Q2 2023; TTM through Jun 2023 was $9.9 million, a N/A change from a year earlier, with the FY2022 full-year figure at $893771.4, changed N/A from the prior year.
- Receivables - Net was $9.9 million for Q2 2023 at Mereo BioPharma, up from $893771.4 in the prior quarter.
- Over five years, Receivables - Net peaked at $9.9 million in Q2 2023 and troughed at $893771.4 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Mereo BioPharma | 38.92 Mn | 38.92 Mn | - |